Jounce Therapeutics, Inc. (JNCE) Research

Jounce Therapeutics, Inc. is an immunotherapy firm currently in the clinical development phase, dedicated to discovering and advancing new cancer treatments. A key asset in its pipeline is vopratelimab, a monoclonal antibody presently in Phase II clinical trials. This therapeutic agent functions by binding to and activating the Inducible T cell CO-Stimulator (ICOS), a specific protein located on the surface of T cells within various solid tumors. The company is also progressing JTX-8064, an antibody designed to target leukocyte immunoglobulin like receptor B2 (LILRB2), a cell surface receptor found on macrophages. Additionally, JTX-1484 is under development, focusing on myeloid targets. Completing its innovative portfolio is JTX-1811, an anti-CCR8 monoclonal antibody precisely engineered to selectively reduce the presence of intra-tumoral T regulatory cells within the tumor's microenvironment. Jounce Therapeutics, Inc. was founded in 2012 and maintains its primary operational base in Cambridge, Massachusetts.

Market snapshot

Symbol
JNCE
Price
$1.88
Day change
0.00%
Market cap
$99.0M
P/E ratio
-1.91x
52-week range
0.5773-5.37
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Aadi Bioscience, Inc. (AADI)
  • Berkeley Lights, Inc. (BLI)
  • Cyteir Therapeutics, Inc. (CYT)
  • Decibel Therapeutics, Inc. (DBTX)
  • HilleVax, Inc. (HLVX)
  • Insight Molecular Diagnostics Inc. (IMDX)
  • Miromatrix Medical Inc. (MIRO)
  • Opiant Pharmaceuticals, Inc. (OPNT)

Recent insider activity

  • Concentra Biosciences, LLC — J-Other (10000 shares) on 2023-05-03
  • TANG KEVIN C — J-Other (10000 shares) on 2023-05-03
  • TANG KEVIN C — U-Tender (5300087 shares) on 2023-05-03
  • Concentra Biosciences, LLC — trade (0 shares) on 2023-05-03
  • Salter-Cid Luisa — D-Return (7850 shares) on 2023-05-03

Open Jounce Therapeutics, Inc. (JNCE) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.